Search

RU-2026113064-A - ANTIBODIES TO TSLP AND THEIR APPLICATIONS

RU2026113064ARU 2026113064 ARU2026113064 ARU 2026113064ARU-2026113064-A

Inventors

  • Ли, Ли

Assignees

  • ФОРТВИТА БАЙОЛОДЖИКС (СИНГАПУР) ПТЕ. ЛТД.

Dates

Publication Date
20260505
Application Date
20241011
Priority Date
20231012

Claims (20)

  1. 1. An antibody or antigen-binding fragment thereof that binds to TSLP (thymic stromal lymphopoietin) containing
  2. a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2 and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
  3. a light chain variable region (VL) comprising CDRs 1, 2 and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to the selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to the selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to the selected VL CDR3 amino acid sequence,
  4. where the selected amino acid sequences of CDRs 1, 2 and 3 of VH and the selected amino acid sequences of CDRs 1, 2 and 3 of VL are one of the following:
  5. (1) selected amino acid sequences of CDRs 1, 2, 3 of VH are shown as SEQ ID NO: 37, 38, 39, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL are shown as SEQ ID NO: 40, 41, 42, respectively;
  6. (2) selected amino acid sequences of CDRs 1, 2, 3 of VH are shown as SEQ ID NO: 86, 38, 39, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL are shown as SEQ ID NO: 40, 41, 42, respectively;
  7. (3) selected amino acid sequences of CDRs 1, 2, 3 of VH are shown as SEQ ID NO: 117, 118, 119, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL are shown as SEQ ID NO: 120, 121, 122, respectively.
  8. 2. The antibody or antigen-binding fragment thereof according to claim 1, wherein VH comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 37, 38, 39, respectively, and VL comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 40, 41, 42, respectively, wherein CDR1 of VH is determined in accordance with the definition by AbM, wherein CDR2 of VH, CDR3 of VH and CDRs 1, 2, 3 of VL are determined in accordance with the definition by Kabat.
  9. 3. The antibody or antigen-binding fragment thereof according to claim 1, wherein VH comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 86, 38, 39, respectively, and VL comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 40, 41, 42, respectively, in accordance with the definition by Kabat.
  10. 4. The antibody or antigen-binding fragment thereof according to claim 1, wherein VH comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 117, 118, 119, respectively, and VL comprises CDRs 1, 2, 3 with the amino acid sequences presented under SEQ ID NO: 120, 121, 122, respectively, in accordance with the definition by Chothia.
  11. 5. An antibody or antigen-binding fragment thereof that binds to TSLP, containing
  12. a heavy chain variable region (VH) comprising an amino acid sequence that is at least 90% identical to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence that is at least 90% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:
  13. (1) the selected VH sequence is the sequence of SEQ ID NO: 43, and the selected VL sequence is the sequence of SEQ ID NO: 44; and
  14. (2) the selected VH sequence is the sequence of SEQ ID NO: 45, and the selected VL sequence is the sequence of SEQ ID NO: 46.
  15. 6. An antibody or antigen-binding fragment thereof according to any one of claims 1-5, wherein the antibody or antigen-binding fragment specifically binds to human TSLP and/or monkey TSLP.
  16. 7. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is a human or humanized antibody or antigen-binding fragment thereof.
  17. 8. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein the antigen-binding fragment is selected from a Fab fragment, a Fab' fragment, an F(ab') 2 fragment, an Fd fragment, an Fv fragment, a dAb fragment, an isolated CDR region, scFv, and a nanoantibody.
  18. 9. An antibody or antigen-binding fragment thereof that binds to TSLP, containing
  19. a heavy chain variable region (VH) comprising VH CDR1, VH CDR2 and VH CDR3 that are identical to VH CDR1, VH CDR2 and VH CDR3 of the selected VH sequence; and a light chain variable region (VL) comprising VL CDR1, VL CDR2 and VL CDR3 that are identical to VL CDR1, VL CDR2 and VL CDR3 of the selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:
  20. (1) the selected VH sequence is the sequence of SEQ ID NO: 43, and the selected VL sequence is the sequence of SEQ ID NO: 44; and